131 related articles for article (PubMed ID: 23113501)
1. Denosumab for post-transplantation hypercalcemia in osteopetrosis.
Shroff R; Beringer O; Rao K; Hofbauer LC; Schulz A
N Engl J Med; 2012 Nov; 367(18):1766-7. PubMed ID: 23113501
[No Abstract] [Full Text] [Related]
2. Denosumab may reduce hypercalcaemia after transplantation for osteopetrosis.
BMJ; 2012 Nov; 345():e7477. PubMed ID: 23135199
[No Abstract] [Full Text] [Related]
3. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
Bowyer SE; White AM; Ransom DT; Davidson JA
Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
[No Abstract] [Full Text] [Related]
4. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
Cicci JD; Buie L; Bates J; van Deventer H
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
[No Abstract] [Full Text] [Related]
5. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
Freeman A; El-Amm J; Aragon-Ching JB
Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
[No Abstract] [Full Text] [Related]
6. Letter to the editor: denosumab for “resistant” hypercalcemia in patients with impaired renal function.
Arampatzis S
J Clin Endocrinol Metab; 2015 Jan; 100(1):L6. PubMed ID: 25559545
[No Abstract] [Full Text] [Related]
7. Denosumab for tumor-induced hypercalcemia complicated by renal failure.
Bech A; de Boer H
Ann Intern Med; 2012 Jun; 156(12):906-7. PubMed ID: 22711097
[No Abstract] [Full Text] [Related]
8. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
9. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
Khoury N; Chang J; Gru AA; Whyte MP
J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
11. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
12. Response letter to the editor.
Hu M
J Clin Endocrinol Metab; 2015 Jan; 100(1):L7. PubMed ID: 25559546
[No Abstract] [Full Text] [Related]
13. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
14. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
15. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
16. Characterization and management of hypercalcemia following transplantation for osteopetrosis.
Martinez C; Polgreen LE; DeFor TE; Kivisto T; Petryk A; Tolar J; Orchard PJ
Bone Marrow Transplant; 2010 May; 45(5):939-44. PubMed ID: 19802031
[TBL] [Abstract][Full Text] [Related]
17. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Adhikaree J; Newby Y; Sundar S
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
[No Abstract] [Full Text] [Related]
18. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Tsuda M; Ishiguro H; Yano I; Toi M
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
[No Abstract] [Full Text] [Related]
19. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
Boikos SA; Hammers HJ
J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
[No Abstract] [Full Text] [Related]
20. [Denosumab finds its way into the updated DVO guidelines].
Fessler B
Med Monatsschr Pharm; 2015 Apr; 38(4):147-8. PubMed ID: 26364385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
